SYRE
Price:
$88.34
Market Cap:
$5.34B
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound ...[Read more]
Industry
Biotechnology
IPO Date
2016-04-07
Stock Exchange
NASDAQ
Ticker
SYRE
According to Spyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.97. This represents a change of -9.42% compared to the average of 9.90 of the last 4 quarters.
The mean historical Current Ratio of Spyre Therapeutics, Inc. over the last ten years is 9.15. The current 8.97 Current Ratio has changed 9.70% with respect to the historical average. Over the past ten years (40 quarters), SYRE's Current Ratio was at its highest in in the June 2016 quarter at 22.88. The Current Ratio was at its lowest in in the June 2023 quarter at 1.03.
Average
9.15
Median
9.44
Minimum
4.06
Maximum
16.75
Discovering the peaks and valleys of Spyre Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 151.42%
Maximum Annual Current Ratio = 16.75
Minimum Annual Increase = -46.11%
Minimum Annual Current Ratio = 4.06
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 13.25 | 17.75% |
| 2024 | 11.26 | 5.39% |
| 2023 | 10.68 | 151.42% |
| 2022 | 4.25 | -13.47% |
| 2021 | 4.91 | -46.11% |
| 2020 | 9.11 | 124.47% |
| 2019 | 4.06 | -45.80% |
| 2018 | 7.49 | -23.35% |
| 2017 | 9.77 | -41.69% |
| 2016 | 16.75 | 10.40% |
The current Current Ratio of Spyre Therapeutics, Inc. (SYRE) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
11.73
5-year avg
8.87
10-year avg
9.15
Spyre Therapeutics, Inc.’s Current Ratio is less than Pharvaris N.V. (11.24), less than Immunome, Inc. (21.68), less than Wave Life Sciences Ltd. (11.26), greater than Intellia Therapeutics, Inc. (6.10), less than Zymeworks Inc. (10.82), less than Maze Therapeutics, Inc. (17.88), less than AbCellera Biologics Inc. (14.05), less than Upstream Bio, Inc. (23.14), greater than Ardelyx, Inc. (3.49), greater than Celldex Therapeutics, Inc. (8.92),
| Company | Current Ratio | Market cap |
|---|---|---|
| 11.24 | $2.29B | |
| 21.68 | $1.79B | |
| 11.26 | $1.19B | |
| 6.10 | $1.76B | |
| 10.82 | $1.70B | |
| 17.88 | $1.42B | |
| 14.05 | $1.69B | |
| 23.14 | $340.12M | |
| 3.49 | $1.49B | |
| 8.92 | $2.16B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Spyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Spyre Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Spyre Therapeutics, Inc. (SYRE)?
What is the highest Current Ratio for Spyre Therapeutics, Inc. (SYRE)?
What is the 3-year average Current Ratio for Spyre Therapeutics, Inc. (SYRE)?
What is the 5-year average Current Ratio for Spyre Therapeutics, Inc. (SYRE)?
How does the current Current Ratio for Spyre Therapeutics, Inc. (SYRE) compare to its historical average?